Detecting the production of radical oxygen species in situ has potential as a novel biomarker. A novel compound (FaSu) for PET imaging of ROS activity and glutamine flux in cancer cells was developed and validated with TRIUMF. FaSu is of clinical interest for assessing tumour response to treatment and/or inflammatory processes. Labeling peptides with 18F without degrading peptide activity with high purity and radiochemical yield is required for clinical development of novel imaging markers. A one-step synthesis for 18F labelling of peptides with clinically relevant purity and doses was developed. The peptide labeling is being developed as a one-step production method for attaching 18F to peptides. My group helped validate FaSu and the peptide labelling methods in pre-clinical models for ROS and angiogenic activity, respectively.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.